260MO - Long term patient reported outcomes in premenopausal women with the hormone receptor positive breast cancer from ABCSG 22 Registry

Background

The present study investigated the long-term Quality of Life (QoL) and sexual health of premenopausal women, on average 9.5 (range 5-15) years after being diagnosed with a HR-positive breast cancer (BC) registered in the ABCSG 22 registry.

Methods

Between April 2008 and January 2022, ABCSG collected Patient Reported Outcome (PRO) data from a registry of premenopausal women with HR-positive BC receiving endocrine therapy with tamoxifen and goserelin for five years (± chemotherapy). After a median follow up of 9 (IQR 8-11) years, a cross-sectional PRO assessment targeting QoL, sexual health and fertility issues was conducted at 11 Austrian centres. PRO was assessed using the EORTC QLQ C30, QLQ-BR45, EORTC QLQ-SHQ22, SABIS, MENQOL and fertility questionnaire. All scores are presented descriptively. Differences between subgroups scores and between register scores and values from reference population were evaluated using MANOVA.

Results

Overall, 469 women were included; the median age was 46 years at BC diagnosis, 55 years at the time of the PRO assessment. 30% of the women had chemotherapy before the start of hormonal therapy. Compared to the general population, women with a history of BC have statistically significant worse score in the emotional and social functional scales of the EORTC C30 as well as more insomnia, constipation, and more financial difficulties. Interestingly, women with a history of BC reported better global health status than the general population (mean 76.9 vs 71.2). Women who had received prior chemotherapy had a statistically significant worse score in the cognitive (mean 80.6 vs 85.8) and social functioning (mean 73.6 vs 80.2) scales of the EORTC C30, more nausea/vomiting, as well as more financial problems compared to the women with endocrine therapy alone. Analyses regarding sexual health, MENQOL and fertility issues is currently ongoing and will also be presented at the meeting.

Conclusions

The long-term side effects of BC therapy and their impact on QoL in premenopausal women are persistent after 10 years of the diagnosis and most pronounced in women who had received additional chemotherapy.

Legal entity responsible for the study

ABCSG, Austrian Breast and Colorectal Cancer Study Group.

Funding

Has not received any funding.

Disclosure

V. Bjelic-Radisic: Non-Financial Interests, Principal Investigator, PI of the EORTC Follow Up 16-17 studyPI of EORTC QLQ BR Update study: EORTC. D. Egle: Financial Interests, Personal, Advisory Board: AstraZeneca, Gilead, Pfizer, Novartis, Lilly, Seagen, Pierre-Fabre, MSD; Financial Interests, Personal, Invited Speaker: Roche, Sirius Medical; Financial Interests, Personal, Expert Testimony: Daiichi Sankyo. F. Haslbauer: Financial Interests, Personal, Invited Speaker: Amgen, AbbVie, Gilead, BMS, Merck Serono; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Servier. F. Fitzal: Financial Interests, Personal, Other, Editor editor for Oncoplastic Surgery part I and II: Springer; Financial Interests, Personal, Other, Mentor: Comena; Financial Interests, Personal, Other, Travel support and scientific support: Roche, AstraZeneca, Pfizer, Myriad, Nanostring, Bondimed (Polytech, Integra), Lilly; Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, Lilly, Roche. R. Greil: Financial Interests, Personal, Advisory Board: Celgene, Novartis, Roche, BMS, Takeda, AbbVie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi; Financial Interests, Personal and Institutional, Funding: Celgene, Roche, Merck, Takeda, AstraZeneca Novartis, Amgen, BMS, MSD, Sandoz, AbbVie, Gilead, Daiichi Sankyo. M. Balic: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Daiichi Sankyo, MSD, Pierre Fabre, Pfizer, Roche, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, Daiichi Sankyo, Eli Lilly, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Gilead; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker, Steering Committee Member, Coordinating PI, Advisory role: Roche; Financial Interests, Institutional, Invited Speaker: Roche, Austrian Breast and Colorectal Cancer Study Group, MSD, Qiagen, Amgen, Pierre Fabre, Novartis, Pfizer, Gilead. R. Bartsch: Financial Interests, Personal, Invited Speaker: AstraZeneca, Seagen, Roche, Novartis, Eli Lilly, Pierre-Fabre, Daiichi, Gilead, MSD, Pfizer, Eisai, Gruenenthal; Financial Interests, Personal, Advisory Board: Daiichi, AstraZeneca, Roche, Novartis, Eli Lilly, Pierre-Fabre, MSD, Gilead, Seagen, Eisai, Gruenenthal; Financial Interests, Institutional, Funding, Investigator Initiated Trial: Daiichi; Financial Interests, Institutional, Invited Speaker, Drug support for investigator initiated trial: MSD. M.I. Gnant: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, Novartis, Pierre Fabre; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Eli Lilly, Menarini-Stemline; Financial Interests, Personal, Expert Testimony: Veracyte; Financial Interests, Invited Speaker: Pfizer; Other, Spouse is employed by Sandoz: Sandoz. All other authors have declared no conflicts of interest.